Web
Analytics
The news is by your side.

impress

Biohaven tumbles as migraine drug efficacy fails to impress investors

Biohaven Pharmaceutical Holding said its migraine treatment met the main goals in two late-stage studies but the efficacy data failed to differentiate when compared with rival treatments in a crowded field. Shares fell as much as 50 percent in light premarket trading on Monday but pared losses to trade down 23 percent at $19 as volume picked up. The stakes are high for Connecticut-based Biohaven, which entered a competitive field late and hopes to rival a treatment from Allergan Plc that reported strong efficacy data…